S100A8和S100A9与肾细胞癌关系的研究进展
The Relationship between S100A8 and S100A9 and Renal Cell Carcinoma
DOI: 10.12677/ACM.2023.1371495, PDF,    科研立项经费支持
作者: 白吉祥, 宋 静, 何春艳：牡丹江医学院附属红旗医院泌尿外科，黑龙江 牡丹江；王书惠*：牡丹江医学院附属红旗医院中西医结合与老年病科，黑龙江 牡丹江
关键词: S100A8；S100A9；钙卫蛋白；肾细胞癌；S100A8； S100A9； Calprotectin； Renal Cell Carcinoma
摘要: 肾细胞癌(renal cell carcinoma, RCC)是泌尿系统中最常见的肿瘤类型之一，在泌尿系统中，发病率居于首位的是前列腺癌，其次是膀胱癌，RCC紧随其后，位居第三。RCC早期发现经治疗后治愈率高，中晚期行肾切除术，术后效果不佳，药物治疗效果亦不显著。S100A8和S100A9隶属于S100蛋白家族，二者可以形成结构稳定的异二聚体——钙卫蛋白，近年来研究显示，S100A8和S100A9与RCC之间具有密不可分的联系。本文对S100A8和S100A9与RCC之间的关系及应用前景进行综述，以期为RCC的诊断、治疗及靶向药物的研发提供更多的思路和方向。
Abstract: Renal cell carcinoma (RCC) is one of the most common types of tumor in the urinary system. In the urinary system, the incidence of prostate cancer is the highest, bladder cancer was second, followed by RCC in third place. If RCC is not found in early stage, the curative rate is high. When RCC develops to middle and late stage, nephrectomy will be performed. S100A8 and S100A9 are members of the S100 protein family, which can form calprotectin, a stable heterodimer. Recent studies have shown that S100A8 and S100A9 are closely related to RCC. This article reviews the relationship between S100A8 and S100A9 and RCC and their application prospect, in order to provide more ideas and directions for the diagnosis, treatment and research and development of targeted drugs for RCC.
文章引用：白吉祥, 宋静, 何春艳, 王书惠. S100A8和S100A9与肾细胞癌关系的研究进展[J]. 临床医学进展, 2023, 13(7): 10707-10712. https://doi.org/10.12677/ACM.2023.1371495

参考文献

[1] Bahadoram, S., Davoodi, M., Hassanzadeh, S., et al. (2022) Renal Cell Carcinoma: An Overview of the Epidemiology, Diagnosis, and Treatment. Giornale Italiano di Nefrologia, 3.
[2] Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[3] 陈磊. 1990-2019年中国肾癌发病与死亡趋势分析及其预测研究[D]: [硕士学位论文]. 衡阳: 南华大学, 2022.[CrossRef] 
[4] 常冬庆, 王勤章, 丁国富, 等. 肾癌116例临床分析[J]. 中华实用诊断与治疗杂志, 2013, 27(7): 702-703.
[5] Patel, H.D., Gupta, M., Joice, G.A., et al. (2019) Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States. European Urology Oncology, 2, 343-348. [Google Scholar] [CrossRef] [PubMed]
[6] Gonzalez, L.L., Garrie, K. and Turner, M.D. (2020) Role of S100 Proteins in Health and Disease. Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, 1867, Article ID: 118677. [Google Scholar] [CrossRef] [PubMed]
[7] 陈思逸, 来茂德. S100家族蛋白与肾癌关系的研究进展[J]. 中国药科大学学报, 2020, 51(2): 223-230.
[8] Chen, H., Xu, C., Jin, Q. and Liu, Z. (2014) S100 Protein Family in Human Cancer. American Journal of Cancer Research, 4, 89-115.
[9] Bresnick, A.R., Weber, D.J. and Zimmer, D.B. (2015) S100 Proteins in Cancer. Nature Reviews Cancer, 15, 96-109. [Google Scholar] [CrossRef] [PubMed]
[10] 王斌, 肖何, 张志敏, 等. 低表达lncRNA LINC00665通过调控S100A13表达抑制膀胱癌侵袭和增殖[J]. 山西医科大学学报, 2020, 51(3): 209-213.
[11] 谢顺明, 王文晓, 赵文武. miR-149-3p通过靶向S100A4抑制膀胱癌细胞的增殖、迁移和侵袭[J]. 现代肿瘤医学, 2019, 27(1): 12-17.
[12] 王妍, 田甜, 王灵芝, 等. 钙结合蛋白S100A1对卵巢癌细胞A2780增殖和迁移的影响[J]. 精准医学杂志, 2018, 33(3): 238-241.
[13] 颜伟, 陈潭琇, 王雅琦, 王灵芝. 沉默S100A10基因对卵巢癌SKOV-3和A2780细胞周期的影响[J]. 实用癌症杂志, 2021, 36(4): 532-535+539.
[14] 胡文兵, 陶泽璋, 费新雄, 等. 鼻咽癌组织中S100A8和S100A9的表达与预后的相关性[J]. 实用医学杂志, 2019, 35(16): 2587-2591.
[15] 曹文波, 莫赛军, 柯少瑞, 等. 钙结合蛋白S100A8和S100A9在慢性炎症相关肿瘤发生中的调控作用[J]. 癌变∙畸变∙突变, 2013, 25(5): 403-406.
[16] Wang, S., Song, R., Wang, Z., et al. (2018) S100A8/A9 in Inflammation. Frontiers in Immunology, 9, Article 1298. [Google Scholar] [CrossRef] [PubMed]
[17] 田圆, 梁群, 潘郭海容, 吴丽丽. 钙卫蛋白S100A8/A9在脓毒症发生发展中的作用机制[J]. 中国感染控制杂志, 2022, 21(11): 1143-1150.
[18] Goyette, J. and Geczy, C.L. (2011) Inflammation-Associated S100 Proteins: New Mechanisms That Regulate Function. Amino Acids, 41, 821-842. [Google Scholar] [CrossRef] [PubMed]
[19] 常如琦, 霍丽娟, 田玲琳, 等. S100A8、S100A9在幽门螺杆菌相关胃癌发生发展中的作用研究进展[J]. 中国微生态学杂志, 2018, 30(8): 973-976+980.
[20] Vogl, T., Eisenblätter, M., Völler, T., et al. (2014) Alarmin S100A8/S100A9 as a Biomarker for Molecular Imaging of Local In-flammatory Activity. Nature Communications, 5, Article No. 4593. [Google Scholar] [CrossRef] [PubMed]
[21] Trinchieri, G. (2012) Cancer and Inflammation: An Old Intuition with Rapidly Evolving New Concepts. Annual Review of Immunology, 30, 677-706. [Google Scholar] [CrossRef] [PubMed]
[22] Balkwill, F. and Mantovani, A. (2001) Inflamma-tion and Cancer: Back to Virchow? Lancet, 357, 539-545. [Google Scholar] [CrossRef] 
[23] Ebbing, J., Mathia, S., Seibert, F.S., et al. (2014) Urinary Calprotectin: A New Diagnostic Marker in Urothelial Carcinoma of the Bladder. World Journal of Urology, 32, 1485-1492. [Google Scholar] [CrossRef] [PubMed]
[24] Zhang, L., Jiang, H., Xu, G., et al. (2015) Proteins S100A8 and S100A9 Are Potential Biomarkers for Renal Cell Carcinoma in the Early Stages: Results from a Proteomic Study Integrated with Bioinformatics Analysis. Molecular Medicine Reports, 11, 4093-4100. [Google Scholar] [CrossRef] [PubMed]
[25] Wu, F., Chen, J., Yao, K., et al. (2022) The Infiltration of Neutrophil Granulocytes due to Loss of PTEN Was Associated with Poor Response to Immunotherapy in Renal Cell Carcinoma. Journal of Inflammation Research, 15, 6553- 6567. [Google Scholar] [CrossRef] 
[26] An, H.J., Koh, H.M. and Song, D.H. (2019) S100A8 Expression May Have a Prognostic Value in CCRCC Reflecting TNM Staging and Fuhrman Nuclear Grade. Anticancer Research, 39, 4681-4685. [Google Scholar] [CrossRef] [PubMed]
[27] Koh, H.M., An, H.J., Ko, G.H., et al. (2019) Prognostic Role of S100A9 Expression in Patients with Clear Cell Renal Cell Carcinoma. Medicine, 98, e17188. [Google Scholar] [CrossRef] 
[28] Zhang, L., Jiang, H., Xu, G., et al. (2016) ITRAQ-Based Quantitative Proteomic Analysis Reveals Potential Early Diagnostic Markers of Clear-Cell Renal Cell Carcinoma. Bio-Science Trends, 10, 210-219. [Google Scholar] [CrossRef] [PubMed]
[29] Mirza, Z., Schulten, H.J., Farsi, H.M., et al. (2015) Molecular Interac-tion of a Kinase Inhibitor Midostaurin with Anticancer Drug Targets, S100A8 and EGFR: Transcriptional Profiling and Molecular Docking Study for Kidney Cancer Therapeutics. PLOS ONE, 10, e0119765. [Google Scholar] [CrossRef] [PubMed]
[30] Mirza, Z., Schulten, H.J., Farsi, H.M., et al. (2014) Impact of S100A8 Expression on Kidney Cancer Progression and Molecular Docking Studies for Kidney Cancer Therapeutics. An-ticancer Research, 34, 1873-1884.
[31] Korndörfer, I.P., Brueckner, F. and Skerra, A. (2007) The Crystal Structure of the Human (S100A8/S100A9)2 Heterotetramer, Calprotectin, Illustrates How Conformational Changes of Interacting α-Helices Can Determine Specific Association of Two EF-hand Proteins. Journal of Molecular Biology, 370, 887-898. [Google Scholar] [CrossRef] [PubMed]

为你推荐